Top

Published in:

01-07-2003 | Drugs and Profile Reports

Pneumococcal 7-valent conjugate vaccine protects young children

Published in: Drugs & Therapy Perspectives | Issue 7/2003

Excerpt

PNCRM7 (Prevnar®¹; Prevenar®) is a pneumococcal 7-valent polysaccharide conjugate vaccine. It protects young children against pneumococcal disease by eliciting a T cell-dependent response. …

Use of tradenames is for product identification purposes only and does not imply endorsement.

Darkes MJM, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002: 4(9): 609–30PubMed

Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccine of healthy infants and young children. JAMA 2000; 283(11): 1460–8PubMedCrossRef

Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Paediatr Health Care 2001; 15(4): 203–8

Eskola J, Anttila M. Pneumococcal conjugate vaccines. Paediatr Infect Dis J 1999; 18(6): 543–51CrossRef

Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR Morb Mortal Wkly Rep 2000 Oct 6; 49 (RR-9): 1–35

Hausdorf WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001; 357: 950–2CrossRef

Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165 Suppl. 1: S49–52PubMedCrossRef

Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6): 403–9PubMedCrossRef

Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM₁₉₇ conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18(9): 757–63PubMedCrossRef

10.

Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19(3): 187–95PubMedCrossRef

11.

Nurka A, Åhman H, Korkeila M, et al. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20(1): 25–33CrossRef

12.

Choo S, Seymour L, Morris R, et al. Immunogenicity and reactogenicity of pneumococcal conjugate vaccine administered combined with Haemophilus influenzae type b conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 2000; 19(9): 854–62PubMedCrossRef

13.

Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM₁₉₇ in United States infants. Pediatrics 1998; 101 (4 Pt 1): 604–11PubMedCrossRef

14.

Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 1999; 29(1): 191–2PubMedCrossRef

15.

Srenson RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17(8): 685–91CrossRef

16.

O’Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM₁₉₇ among infants with sickle cell disease. Pediatrics 2000; 106(5): 965–72PubMedCrossRef

17.

Choo S, Zhang Q, Seymour L, et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000; 182(4): 1260–3PubMedCrossRef

18.

Black SB, Shinefield HR, Hansen J, et al. Postlicense evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20(12): 1105–7PubMedCrossRef

19.

Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171: 885–9PubMedCrossRef

20.

British National Formulary 44 [online]. Available from URL: http://www.bnf.org.uk [Accessed 2003 Mar 13]

21.

Prevnar, pneumococcal 7-valent conjugate vaccine (diphtheria CRM₁₉₇ protein) [prescribing information]. Pearl River (NY): Lederle Laboratories, 2001

Title: Pneumococcal 7-valent conjugate vaccine protects young children
Publication date: 01-07-2003
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 7/2003
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/00042310-200319070-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pneumococcal 7-valent conjugate vaccine protects young children

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2003

New in the marketplace

The usefulness of splitting tablets as a cost-saving strategy is limited

Imatinib Mesylate in GIST: profile report

It may be possible to prevent restenosis by targeting oxidative stress

Ocular allergy: avoidance of allergens and symptomatic therapy still the mainstay of treatment for most patients

First reports of adverse drug reactions (ADRs) in recent weeks